April 25, 2022
OnKure Therapeutics Expands Boulder Footprint with the Opening of a New Research Laboratory
April 8, 2022
OnKure Therapeutics Announces Promising Preclinical Data on OKI-179 in RAS-Mutated Tumor Models Presented in a Late-Breaking Session at AACR
March 8, 2022
OnKure Therapeutics to Present Late-Breaking Preclinical Data on OKI-179 at the AACR Annual Meeting 2022
OnKure is committed to the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancer. As a team of veterans with a track record of successful drug discovery and development, we are leveraging our proven structure-based drug design approach to create a robust pipeline of drug candidates that are designed to achieve optimal tolerability and efficacy. OnKure is currently developing its lead clinical candidate OKI-179, an oral Class I HDAC inhibitor, for the treatment of both hematological and solid tumors, as well as exploring other validated oncology targets and pathways. In the evolving landscape of precision oncology, our successful tumor-agnostic approach is key to discovering new treatments for cancer patients with unmet medical needs.